股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | FF301 ...

Core Insights - The announcement of a strategic investment by Mr. Gong Hongjia, a prominent figure in the investment and industry sectors, marks a significant milestone for China Biotechnology Services (08037), as it plans to issue $35 million (approximately HKD 272 million) in convertible bonds, indicating a strong signal of confidence in the industry and resource integration value beyond mere financial injection [1][2][8] Group 1: Strategic Investor Entry - Mr. Gong Hongjia is recognized for his extensive experience in the healthcare and telecommunications sectors, having created several industry benchmarks and ranked 29th on the 2022 Forbes China Rich List [2] - His investment philosophy emphasizes "patient capital," which supports long-term enterprise development, exemplified by his successful angel investment in Hikvision [2][3] Group 2: Business Alignment and Synergy - Mr. Gong's strategic investment aligns closely with China Biotechnology Services' focus on BNCT (Boron Neutron Capture Therapy) and its comprehensive strategy involving detection services, CAR-T cell therapy, and BNCT, creating a strong complementary resource base [3][4] - The investment is seen as a deep recognition of the company's business layout, development stage, and core technology value, forming a "golden combination" of critical phases, investors, and business focus [3][4] Group 3: BNCT Technology and Market Dynamics - The investment highlights Mr. Gong's focus on the advancements in BNCT, a leading cancer radiotherapy technology known for its precision targeting and minimal side effects, which has shown significant potential in clinical applications [4][5] - The establishment of the Pengbo (Hainan) BNCT Hospital is a key initiative for capturing the BNCT market, with plans to commence patient treatment in early 2026, following the successful acquisition of advanced BNCT treatment systems [5][6] Group 4: Policy and Market Drivers - The strategic partnership coincides with a favorable period for the BNCT industry, characterized by supportive policies and increasing market demand, as the technology has been prioritized for expedited approval by regulatory authorities [6] - The rising cancer incidence and the urgent need for precise treatment solutions position BNCT as a promising innovation, with China Biotechnology Services leveraging its first-mover advantage and advanced equipment to establish significant industry barriers [6][7] Group 5: Future Outlook - The collaboration with Mr. Gong is expected to catalyze a second growth phase for China Biotechnology Services, breaking previous development bottlenecks and enhancing the integration of industry resources [8] - With ongoing policy support and rapid market growth, the company aims to deepen its strategic layout centered on BNCT, accelerating the industrialization of technology and the integration of services [8]

Core Viewpoint - The announcement of a strategic investment by Mr. Gong Hongjia through the issuance of a $35 million convertible bond marks a significant milestone for China Biotechnology Services, indicating a strong partnership that will enhance the company's core business and industry chain layout [1][8]. Group 1: Strategic Investor Entry - Mr. Gong Hongjia is a prominent figure in the investment and industry sectors, known for his deep insights in healthcare and telecommunications, and has a successful track record, including angel investment in Hikvision [2]. - His investment philosophy emphasizes "patient capital," which supports long-term enterprise development, further enhancing the credibility of the investment [2]. Group 2: Core Business Alignment - The strategic investment focuses on China Biotechnology Services' advancements in BNCT (Boron Neutron Capture Therapy), a leading cancer radiotherapy technology with significant clinical potential [4][5]. - The establishment of the Pengbo (Hainan) BNCT Hospital is a key initiative to capture the BNCT market, with plans to begin patient treatment in early 2026 [5]. Group 3: Policy and Market Drivers - The partnership coincides with a favorable policy environment for the BNCT industry, as it has been prioritized for expedited approval by the National Medical Products Administration and included in the "14th Five-Year Plan" as a key emerging industry [6]. - The increasing cancer incidence and demand for precise treatment solutions position BNCT as a promising market opportunity, with China Biotechnology Services leveraging its first-mover advantage in Hainan [6]. Group 4: Summary and Outlook - The collaboration with Mr. Gong Hongjia represents a transformative event for China Biotechnology Services, facilitating a breakthrough in development bottlenecks and initiating a second growth phase [8]. - The company aims to capitalize on policy benefits and market demand, focusing on BNCT technology and synergizing with Mr. Gong's enterprises to enhance its strategic layout and achieve significant growth [8].

Group 1 - The company has entered into a subscription agreement with Fucai Holdings to issue convertible bonds totaling $35 million (approximately HKD 272.3 million) [1] - The initial conversion price is set at HKD 0.66 per share, which could lead to the issuance of up to 412.6 million shares, representing approximately 42.28% of the total shares currently issued [1] - If the conversion rights are fully exercised, the total issued share capital will increase by approximately 29.72%, assuming no changes in the company's issued capital from the announcement date until conversion [1] Group 2 - The board believes that the subscription will strengthen the company's capital base and prepare for long-term development and improved financial status [2] - Issuing convertible bonds will not cause immediate dilution of existing shareholders' equity [2] - The company sees the issuance of convertible bonds as an opportunity to expand and strengthen its capital base while attracting new investors to broaden its shareholder base [2]

Core Viewpoint - China Biotechnology Services (08037) has entered into a subscription agreement with Fucai Holdings to issue convertible bonds worth $35 million, equivalent to approximately HKD 272.3 million, aimed at strengthening the company's capital base and financial position [1] Group 1: Convertible Bonds Issuance - The company has conditionally agreed to issue convertible bonds with a principal amount of $35 million [1] - The initial conversion price is set at HKD 0.66 per share, which is subject to adjustment [1] - If the conversion rights attached to the bonds are fully exercised, up to 412.6 million shares will be issued, representing approximately 42.28% of the total shares currently in issue [1] Group 2: Impact on Shareholders - The issuance of convertible bonds will not cause immediate dilution of existing shareholders' equity [1] - If the conversion rights are exercised, the total number of shares issued will increase by approximately 29.72%, assuming no changes in the company's issued share capital from the announcement date until conversion [1] Group 3: Investor Profile - The subscriber, Fucai Holdings, primarily engages in investment activities across various sectors, including life sciences, education, internet, technology media, and telecommunications, managing assets exceeding $100 million [1] Group 4: Strategic Rationale - The board believes that the subscription will enhance the company's capital foundation, preparing for long-term development and improving financial conditions [1] - The issuance of convertible bonds is seen as an opportunity to expand and strengthen the capital base while attracting new investors to broaden the shareholder base [1]

Core Viewpoint - China Biotechnology Services (08037.HK) has entered into a subscription agreement with Fucheng Holdings Limited for the issuance of convertible bonds totaling $35 million, equivalent to approximately HKD 272.3 million, with a conversion price set at HKD 0.66 per share, representing a discount of about 16.46% from the closing price of HKD 0.79 on the agreement date [1] Group 1 - The total principal amount of the convertible bonds is $35 million, which will result in a maximum issuance of approximately 413 million shares, accounting for about 42.28% of the total shares outstanding as of the announcement date [1] - The net proceeds from the issuance of the convertible bonds are expected to be approximately $33.9 million [1] - The company plans to allocate 47.6% of the net proceeds for repaying other loans' principal and interest [1] Group 2 - 25.8% of the net proceeds will be used for the development and construction of a network of boron neutron capture therapy centers for cancer treatment [1] - 5.7% of the net proceeds will be allocated for research and development costs [1] - 20.9% of the net proceeds will be utilized for general working capital purposes [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 建議根據特別授權 發行可轉換債券 建議發行可轉換債券 於二零二五年十二月二十九日（聯交所交易時段後），本公司與認購人訂立認購 協議，據此，本公司已有條件同意發行，而認購人已有條件同意認購本金總額 為35,000,000美元（相等於約272,300,000港元）之可轉換債券。 按初步換股價每股換股股份0.66港元（可予調整）計算，當可轉換債券附帶之換 股權獲悉數行使，最多412,575,758股換股股份將予以配發及發行，相當於(i)本 公告日期已發行股份總數約42.28%；及(ii)經於可轉換債券獲悉數轉換時配發及 發行換股股份擴大之已發行股份總數約29.72%（假設自本公告日期起直至可轉 換債券按初步換股價獲悉數轉換為止， ...

公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月3 ...

Core Insights - The flagship project of China Biotech Services, the Pengbo (Hainan) Boron Neutron Hospital, has achieved a significant milestone by successfully achieving the first neutron beam output from its NeuCure® neutron irradiation system, marking a critical advancement in the project timeline [1] Company Developments - The hospital is located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, which provides supportive policy advantages for its operations [1] - The NeuCure® system is the only boron neutron therapy system globally that has received formal medical device registration and can be applied directly in routine clinical treatment, rather than being limited to clinical trials [1] - Clinical treatment services using this system are expected to officially commence in the first quarter of 2026 [1] Project Progress - The successful beam output confirms that the core components of the system meet the design specifications, transitioning the project from equipment installation to beam commissioning [1] - This milestone lays a solid foundation for subsequent critical tasks, including precise neutron dose rate control, beam physics validation, and biological effect assessment [1] - The advancement ensures that the equipment can proceed with high standards in clinical treatment, providing safe and precise boron neutron therapy services for cancer patients [1]

Core Insights - China Biotechnology Services (08037) announced significant progress for its flagship project, Pengbo (Hainan) Boron Neutron Hospital, located in the Boao Lecheng International Medical Tourism Pilot Zone, with the successful first beam output of the NeuCure neutron irradiation system [1] - The system is the only boron neutron capture therapy system globally that has received formal medical device registration and can be directly applied in routine clinical treatment, with clinical services expected to commence in Q1 2026 [1] - The successful beam output confirms that the core components of the system meet design specifications, marking a transition from equipment installation to beam commissioning, which is crucial for subsequent precise neutron dose rate control and biological effect evaluation [1] Company Developments - The NeuCure neutron irradiation system has entered the final clinical debugging phase, establishing a solid foundation for the hospital's future operations [1] - The project benefits from supportive policies in the Boao Lecheng International Medical Tourism Pilot Zone, enhancing its operational viability [1] - The achievement of this milestone ensures that the equipment can advance clinical treatment at a high standard, providing safe and precise boron neutron therapy services for cancer patients [1]